Clinical trials: Skin Diseases, Genetic
Cryopyrin-Associated Periodic Syndrome
Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)
This is a Phase 2 study to investigate the safety and efficacy of ATI-450 for the Maintenance of Remission in Patients with Cryopyrin-Associated Periodic Syndrome (CAPS) Previously Managed with Anti-IL-1 Therapy.
- Trial name
- NCT04524858
- Testing
- ATI-450
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Aclaris Therapeutics, Inc.
Familial Partial Lipodystrophy
The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy
The purpose of this study is to evaluate the efficacy and safety of volanesorsen given for 52 weeks in a randomized treatment (RT) period in participants with familial partial lipodystrophy (FPL).
- Trial name
- NCT02527343
- Testing
- volanesorsen
- Where
- 12 sites in United States, Belgium and 5 more
- Volunteers
- 40 people
- Sponsor
- Akcea Therapeutics
Atopic Dermatitis
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)
This is a randomized, double-blind, placebo-controlled, parallel-group study which is 52 weeks in duration. The study is designed to confirm the safety and efficacy of lebrikizumab as monotherapy for treatment of…
- Trial name
- NCT04146363
- Testing
- Lebrikizumab
- Where
- 94 sites in United States, Australia and 8 more
- Volunteers
- 424 people
- Sponsor
- Eli Lilly and Company
Bullous Keratopathy, Corneal Erosion
AONDA Therapeutic Indication Study I
This study will be used to support assessment of AIR OPTIX® NIGHT \& DAY® AQUA (AONDA) Soft Contact Lenses' safety and performance in accordance with updated European Union Medical Device Regulation (EU MDR) requirements.
- Conditions
- Bullous Keratopathy, Corneal Erosion, Entropion, Corneal Edema
- Trial name
- NCT05891106
- Testing
- Lotrafilcon A contact lenses
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- Alcon Research
Hereditary Breast and Ovarian Cancer
CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing
This is a mixed-methods Hybrid Type 1 research design (efficacy study) in which we aim to conduct a two-arm randomized controlled trial and an Implementation Focused Process Evaluation of a culturally-targeted video and referral…
- Trial name
- NCT05130606
- Testing
- Culturally Targeted Narrative Video: "Is My Cancer Hereditary? Rosa Visits a Genetic Counselor.", FORCE Fact Sheet
- Where
- 2 sites in United States
- Volunteers
- 332 people, healthy volunteers welcome
- Sponsor
- Georgetown University
Dermatitis, Atopic
To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis
This is a Phase II, randomized, double-blind, placebo-controlled study in subjects with moderate to severe atopic dermatitis.
- Trial name
- SOLARES-AD-1 (NCT04684485)
- Testing
- SCD-044_Dose 1, SCD-044_Dose 2, SCD-044_Dose 3
- Where
- 58 sites in United States, El Salvador and 3 more
- Volunteers
- 250 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST)
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
The purpose of this study was to allow continued use of nilotinib in patients who were on nilotinib treatment in a Novartis-sponsored, Oncology Clinical Development \& Medical Affairs (CD\&MA) study and were benefiting from the…
- Conditions
- Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST), Acute Lymphoblastic Leukemia (ALL), Receptor Tyrosine Kinase (KIT) Mutated Melanoma
- Trial name
- NCT01735955
- Testing
- Nilotinib
- Where
- 33 sites in United States, Austria and 14 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
Effect of Pimecrolimus Cream on Cathelicidin Levels in Subjects With Eczema
The purpose of this study is to determine the effect of topical pimecrolimus on the immune system by assessing the levels of antimicrobial peptides in the skin of patients with eczema.
- Trial name
- NCT00946478
- Testing
- Pimecrolimus, Vehicle cream
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of California, San Diego
Breast Cancer, Ovarian Cancer
EHR Intervention to Increase HBOC Genetic Testing
The purpose of this research study is to test how well a new approach - using tools built into the electronic health record (EHR)- can help increase genetic testing for hereditary breast and ovarian cancer (HBOC) in women who…
- Conditions
- Breast Cancer, Ovarian Cancer, Hereditary Cancer Syndrome
- Trial name
- ELISABETH (NCT07876349)
- Testing
- ELISABETH Evidence-Informed Program (EIP)
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Columbia University
Atopic Dermatitis (AD)
Efficacy and Safety of Revodiol Calming Cream® in Atopic Dermatitis.
A 56-day clinical study evaluated Revodiol Calming Cream on pediatric and adult participants with mild to moderate atopic-prone skin under dermatological supervision.
- Trial name
- NCT07301658
- Testing
- Novel dermocosmetic product containing cannabidiol (CBD) and Annona cherimola fruit extract.
- Where
- Spain
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- i+Med S.Coop.
Allergic Rhinitis, Asthma
The Significance of Ambrosia in Allergic Rhinitis and Asthma in Israel
Ambrosia is known for its allergenicity in the USA causing hay fever and asthma. Israel has always been considered "clean" of Ambrosia but over the past years growth of Ambrosia plants has been detected in several locations in…
- Conditions
- Allergic Rhinitis, Asthma, Allergic Conjunctivitis, Atopic Dermatitis
- Trial name
- NCT01686048
- Where
- Israel
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Meir Medical Center
Mucopolysaccharidoses
Respiratory Cathepsins, Proteases Inhibitors and Glycosaminoglycans (GAG) in Mucopolysaccharidosis
Mucopolysaccharidosis (MPS) are a group of inherited, metabolic diseases caused by a deficiency of lysosomal enzymes that degrade glycosaminoglycans (GAGs).
- Trial name
- RespiGAG (NCT04112602)
- Testing
- Sputum, Tracheal aspiration
- Where
- 7 sites in France
- Volunteers
- 27 people
- Sponsor
- University Hospital, Tours
Cancer, Breast Cancer
Liquid Biopsy Evaluation and Repository Development at Princess Margaret
The objective of this protocol is to develop an institution-wide liquid biopsy protocol that will establish a common process for collecting blood and corresponding archived tumor specimens for future research studies at the…
- Conditions
- Cancer, Breast Cancer, Lung Cancer, Colon Cancer
- Trial name
- LIBERATE (NCT03702309)
- Where
- Canada
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Atopic Dermatitis, Food Allergy
An Innovative Probiotic Product With Antiallergic Properties
Allergic diseases are currently one of the most important problem in medicine. Research confirms that probiotics administered during the formation of the intestinal ecosystem and the maturation of the immune system can positively…
- Conditions
- Atopic Dermatitis, Food Allergy, Effects of Probiotics
- Trial name
- NCT04738565
- Testing
- Probiotic preparation, Maltodextrin
- Where
- Poland
- Volunteers
- 150 people
- Sponsor
- Children's Memorial Health Institute, Poland
Breast Cancer
A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6
The investigators plan to examine endoxifen and 4-OH-Tam as a function of the tamoxifen dose in patients with a genetic CYP2D6 polymorphism.
- Trial name
- NCT00900744
- Testing
- Tamoxifen
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Sjögren-Larsson Syndrome
A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)
This is a multi-center, randomized, double-blind, vehicle-controlled, parallel-group study designed to evaluate the safety, pharmacokinetic (PK), and exploratory activity of topically-applied NS2 dermatologic cream administered…
- Trial name
- NCT02402309
- Testing
- Active topical NS2 1% dermatologic cream
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Dermatitis, Atopic
Phase IIa Study of WBI-1001 Cream for Atopic Dermatitis
WBI-1001 is a synthetic,new, non-steroid, small molecule being developed as a candidate drug for the topical, cream treatment of inflammatory skin diseases.
- Trial name
- WBI-1001-201 (NCT00837551)
- Testing
- WBI-1001
- Where
- Canada
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Welichem Biotech Inc.
Epidermolysis Bullosa Dystrophica, Recessive
A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
The purpose of this study is to evaluate the safety of FCX-007, evaluate Type VII collagen (COL7) expression and the presence of anchoring fibrils and to analyze wound healing as a result of FCX-007 administration in subjects…
- Trial name
- NCT02810951
- Testing
- FCX-007
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Castle Creek Biosciences, LLC.
Atopic Dermatitis, Pruritus
Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone
Purpose: To study the etiology and the epigenetic pathways leading to and regulating chronic itch. Similarly, to examine the mechanisms underlying skin changes, including epigenetic alterations while also testing the efficacy of…
- Conditions
- Atopic Dermatitis, Pruritus, Pruritus Chronic, Dermatitis
- Trial name
- NCT04325802
- Testing
- Naltrexone
- Where
- United States
- Sponsor
- University of Minnesota
Triple Negative Breast Neoplasms
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
This trial studies ladiratuzumab vedotin (LV) with pembrolizumab in patients with triple-negative breast cancer. It will find out what side effects happen when participants get these two drugs.
- Trial name
- NCT03310957
- Testing
- ladiratuzumab vedotin, Pembrolizumab
- Where
- 50 sites in United States, Germany and 2 more
- Volunteers
- 185 people
- Sponsor
- Seagen Inc.